Hosted on MSN2h
Parkinson's disease could be treated by FDA-approved cancer drug after major research breakthroughA major research breakthrough on Parkinson's disease revealed that an already FDA-approved cancer drug could help stem the ...
(RTTNews) - Replimune Group, Inc. (REPL), Tuesday announced that the U.S. Food and Drug Administration has accepted the Biologics License Application for RP1 in combination with Nivolumab for the ...
ScienceAlert on MSN6d
Parkinson's Discovery Suggests We Could Already Have an FDA-Approved TreatmentResearchers have discovered how a cell surface protein called Aplp1 can play a role in spreading material responsible for ...
CheckMate 649 trial showed sustained efficacy with frontline nivolumab plus chemotherapy vs chemotherapy alone in patients with gastric cancers.
The FDA has accepted a BLA for treatment with RP1 in combination with Opdivo for patients with advanced melanoma who have ...
Dr. Balazs Halmos discusses the significance of the approval of subcutaneous Opdivo and what this treatment formulation means ...
The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in Chinese patients with advanced gastric, gastroesophageal junction, and ...
The confirmatory IGNYTE-3 trial is assessing RP1 in combination with nivolumab in patients with advanced melanoma who have progressed on anti-PD-1 and anti-CTLA-4 therapies or are ineligible for ...
The FDA grants Priority Review to applications for medicines that, if approved, provide significant ... designation for RP1 in combination with nivolumab for the treatment of advanced melanoma ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback